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Ninety percent of anal cancer is associated with human papilloma viruses (HPVs). Using our previously estab-
lished HPV transgenic mouse model for anal cancer, we tested the role of the individual oncogenes E6 and E7.
K14E6 and K14E7 transgenic mice were treated with dimethylbenz[a]anthracene (DMBA) to the anal canal
and compared to matched nontransgenic and doubly transgenic K14E6/E7 mice. K14E7 and K14E6/E7 trans-
genic mice developed anal tumors (papillomas, atypias and carcinomas combined) at signiﬁcantly higher
rates (88% and 100%, respectively) than either K14E6 or NTG mice (18% and 19%, respectively). Likewise,
K14E7 and K14E6/E7 transgenic mice developed frank cancer (carcinomas) at signiﬁcantly higher rates
(85% and 85%, respectively) than either K14E6 or NTG mice (18% and 10%, respectively). These ﬁndings indi-
cate that E7 is the more potent oncogene in anal cancer caused by HPVs.
© 2011 Elsevier Inc. All rights reserved.ncer Research, 1400 University
rights reserved.Introduction
There are approximately 30,000 cases of anal cancer per year
worldwide of which 90% are attributable to infection with high risk
HPV (Parkin, 2006). HPV16 is the high risk HPV genotype most com-
monly found in anal cancer (Cogliano et al., 2005). HPV 16 encodes
two oncoproteins that target key cellular tumor suppressors. E6
binds to p53 leading to deregulation of DNA damage and apoptotic
pathways. E7 targets pRb for degradation, leading to an increase in
cell proliferation and genomic instability. HPV has oncogenic proper-
ties in multiple squamous epithelial sites including the cervix, vulva,
anus and a subset of head and neck.
The incidence of anal cancer has been rising gradually in the US
over the past thirty years, with overall incidence in the general popu-
lation now at 1.5 persons per 100,000 persons (Ries et al., 1975–2005,
SEER Cancer Statistics Review). The National Cancer Institute esti-
mates that 5260 people (3260 women and 2,000 men) were diag-
nosed with anal cancer in the United States in 2010. HIV
seropositivity is among the risk factors for developing anal cancer;
others include low CD4 count, persistent high risk HPV infection, in-
fection with multiple HPV types, anoreceptive intercourse, history of
cervical cancer or dysplasia, cigarette smoking and immunosuppres-
sion for organ allograft (Welton et al., 2004). In the HAART era, HIV-
infected patients have an incidence of anal cancer of ~40 per
100,000 persons, rising to 78 per 100,000 among HIV-infected men
who have sex with men (Patel et al., 2008; Piketty et al., 2008).
While 50% of patients present with disease conﬁned to the primarysite and these patients have a favorable (80%) 5-year survival rate,
the remainder of the patients present with regional or distant metas-
tasis correlating with less favorable 61% and 21% survival rates, re-
spectively (Ries et al., 1975–2005). Anal cancer treatment has
essentially remained static over the past two decades. The high rate
of mortality from advanced anal cancer speaks to the need for more
effective clinical interventions for patients with advanced disease.
Prophylactic vaccines against speciﬁc HPV genotypes including
HPV16 are already making an impact on HPV-associated human dis-
ease. After a population wide vaccination program was implemented
for young women, there was signiﬁcantly decreased incidence of high
grade cervical squamous intraepithelial lesions from 0.85% down to
0.38% (pb0.01) (Brotherton et al., 2011). For anal cancer, the highest
risk groups are men who have sex with men and men with AIDS
(Chaturvedi et al., 2009; Cress and Holly, 2003). Prophylactic vaccines
have now been shown to be safe and immunogenic in men and have
potential to prevent a large portion of HPV-related squamous cell anal
carcinoma by preventing the cancer-initiating HPV infection event
(Franceschi and De Vuyst, 2009; Moreira et al., 2011). But prophylac-
tic vaccines will not prevent anal cancers in patients already infected
with high risk HPVs or who already have anal cancer. In these groups,
therapeutic vaccines or medications may be needed to target onco-
genes. Studies on therapeutic vaccines thus far have proven difﬁcult
to dissect the relative contributions of the vaccine vs the natural
human immune system (Frazer et al., 2011). New medications that
can target HPV oncogenes or the cellular pathways they affect could
have signiﬁcant impact on improving clinical outcome for patients
with anal cancer, as with other HPV-associated cancers.
Anal cancer is one of the least well-studied HPV-associated can-
cers because of the absence of laboratory model systems with which
to pursue experiments. We have focused over the past few years at
115M.K. Thomas et al. / Virology 421 (2011) 114–118establishing mouse models for the purpose of understanding the role
of HPVs in anal cancer and identify potential targets for new thera-
peutic approaches to treat this cancer. Speciﬁcally, we generated the0
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HPV16 transgenic mice that express E6 or E7 in stratiﬁed squamous
epithelia of various organs (Stelzer et al., 2010b). We ﬁrst established
that HPV16 E6 and E7 are expressed and functional in the anal epithe-
lium of our K14E6 and K14E7 transgenic mice, where they induced
hyperproliferation and abrogated DNA damage response. These
mice do not spontaneously develop anal cancer indicating that
other genetic/epigenetic changes are required for carcinogenesis,
much like with other HPV-associated cancers. Because we had previ-
ously demonstrated that HPV16 E6 and E7 synergize with the chem-
ical carcinogen DMBA to cause skin cancers (Song et al., 2000), we
monitored anal cancer in K14E6/K14E7 double transgenic mice trea-
ted topically with DMBA (0.12 μmol administered to the anal canal
once per week for 20 weeks), and held an additional 8 weeks prior
to sacriﬁce. A strong synergy between DMBA and the viral oncogenes
was demonstrated, with a progressive neoplastic disease culminating
in malignancy arising within the anal epithelium of the K14E6/K14E7
mice. Biomarker expression paralleled that observed in human anal
neoplastic disease, providing further validation of this animal
model. Using this model we also identiﬁed the MTOR pathway to be
activated in anal cancers, and these cancers to be responsive to rapa-
mycin (Stelzer et al., 2010a).
The goal of the present study was to deﬁne the relative contribu-
tions of HPV16 E6 and E7 in anal cancer. In previously established cer-
vical and head and neck cancer models, E7 had been identiﬁed to be
the more potent oncogene (Riley et al., 2003; Strati and Lambert,
2007). HPV induced skin cancer models, however, revealed E6 as
the primary contributor to carcinogenesis (Song et al., 2000). We
thus sought to discover the contribution of the individual oncogenes
in anal cancer using our newly established anal cancer transgenic
mouse model (Stelzer et al., 2010b). We evaluated the acute pheno-
types of singly transgenic (E6 and E7 only) vs doubly transgenic
(E6/E7) and nontransgenic (NTG) anal epithelium. E7 and to lesser
degree E6 could induce proliferation within the anal epithelium,
while both could abrogate normal DNA damage responses, akin to
what has been observed in other epithelial tissues. To evaluate carci-
nogenesis, cohorts of mice of each genotype had DMBA applied to the
perianal area and tumor development was monitored. The E7 only
mice and E6/E7 mice had an 85% incidence of anal cancer which
was signiﬁcantly higher than E6 only and NTG mice, 18% and 10% re-
spectively. The tumors that developed in E7 only and E6/E7 mice
were larger and appeared earlier. These ﬁndings indicate that E7 is
the more potent oncogene for anal carcinogenesis.
Results
HPV16 E6 and E7 induce acute phenotypes in the anal epithelium
commensurate with their known in vivo activities in other tissues
We previously established by Western analyses that HPV16 E6
and E7 oncoproteins are expressed in the anal epithelium of these
mice at levels commensurate with that found in human HPV-positive
cancer-derived cell lines (Stelzer et al., 2010b). To assess the functionFig. 1. Acute phenotypes of HPV16 transgenic mouse anal epithelium. Panel A. Shown
is MCM7-speciﬁc and BrdUrd immunohistochemical staining of sections from the anus
of nontransgenic (NTG), E6, E7 and E6/E7 transgenic mice. Strong induction of MCM7
occurs in E7 and E6/E7 anal epithelium compared to NTG and E6 anal tissue. Similar
staining is seen with BrdUrd staining with suprabasal DNA synthesis occurring more
frequently in E7 and E6/E7 mice. Brown nuclei indicate positive staining which is
expected along the basement membrane (outlined in black) as seen in NTG mice.
Panel B. Quantiﬁcation of the percentage of suprabasal cells with BrdUrd-positive nu-
clei. Panel C. Response of anal epithelium to radiation-induced growth arrest. Shown
is the quantiﬁcation of the frequency of BrdUrd-positive basal cells in anal epithelia
of HPV transgenic mice that were (+) or were not (−) treated with 12 Gy (γ) external
radiation.
Table 1
E6/E7 and E7 transgenic mice confer signiﬁcantly higher rates of tumor and carcinoma
incidence.
Genotype n Phenotype Histopathological Classiﬁcation of Disease
Overt Tumor Normal Papilloma Atypia Cancer
NTG 21 4 (19%) 16 0 3 2 (10%)
E6 33 6 (18%) 24 0 3 6 (18%)
E7 33 29 (88%)* 2 0 3 28 (85%)†
E6/E7 20 20 (100%)* 0 0 3 17 (85%)†
*pb0.01 for E7 or E6/E7 tumors compared to E6 or NTG tumors.
†pb0.01 for E7 or E6/E7 cancers compared to E6 or NTG cancers.
p-Values were calculated using two-sided Chi square test.
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116 M.K. Thomas et al. / Virology 421 (2011) 114–118of each oncoprotein in anal tissue, acute phenotypes of E6 only
(K14E6) and E7 only (K14E7) mice were compared to doubly trans-
genic E6/E7 (K14E6/K14E7) mice and NTG mice.
The HPV E7 oncoprotein is known to induce the transcription of
E2F-responsive genes through its inactivation of pRb, p107 and
p130 (Chellappan et al., 1992; Dyson et al., 1992; McLaughlin-Drubin
andMunger, 2009; Phelps et al., 1988). One such E2F-responsive gene
is minichromosome maintenance 7 (MCM7), a gene we have previ-
ously identiﬁed to be an informative marker for HPV-associated can-
cers of the cervix (Brake et al., 2003), head and neck region (Strati
et al., 2006) and anus (Stelzer et al., 2010b). Immunohistochemistry
for minichromosome maintenance 7 (MCM7) was performed on
anal tissue harvested from mouse genotypes NTG, E6, E7 and E6/E7
that were or were not subjected to radiation one day prior to sacriﬁce.
E7 only mice stained positive for MCM7 similar to E6/E7 mice while
E6 only mice resembled NTG mice in their staining pattern (Fig. 1A).
This was the expected pattern of staining given the importance of E7 in
dysregulating E2Fs. Nextwemonitored levels of proliferation by scoring
for the frequency of cells supportingDNA synthesis. For this purposewe
injected mice with bromodeoxyuridine (BrdUrd) 1 hour prior to sacri-
ﬁce and subjected sections of anal epithelium frommice to BrdUrd-spe-
ciﬁc immunohistochemistry. E7 and to a lesser degree E6, has been
shown to induce DNA synthesis in suprabasal cells of other epithelium
for instance of the skin (Gulliver et al., 1997; Song et al., 1999), cervix
(Brake et al., 2003; Shai et al., 2007) and tongue (Strati and Lambert,
2007). E7 only (11%) and E6/E7 (26%) mice had signiﬁcantly higher
DNA synthesis in supra basal cells compared to both NTG (0.5%) and
E6 only (3%) anal epithelium (Fig. 1B). Lastly, we monitored the ability
of both E6 and E7 to abrogate normal DNA damage responses in basal
cells of the anal epithelium. In other tissues including the skin (Song
et al., 1998) and cervix (Shai et al., 2007), both E6 and E7 abrogate the
normal response of epithelium to ionizing radiation, which is a cessa-
tion of DNA synthesis within the ﬁrst 24 hours following exposure to
ionizing radiation. Only anal epithelium from NTGmice had the appro-
priate DNA damage response with signiﬁcantly decreased proliferation
24 hours after radiation exposure (Fig. 1C). These results indicate that
both E6 and E7 are functional within the anal epithelium, providing us
cause to pursue the individual roles of these two viral oncoproteins in
anal carcinogenesis.NTG E6 E7 E6/E7
0
Fig. 2. Overt tumor characteristics. Panel A. Tumors more frequently occurred in E7 and
E6/E7 mice and were larger in size. Average tumor size was 7 mm in E6/E7 mice,
8.3 mm in E7 mice while it was 3.75 in NTG mice and 1.3 in E6 mice. Differences in
the size of tumors between either the E7 and E6/E7 mice or E6 mice were highly signif-
icant (pb0.01). However there was no signiﬁcant difference in either criteria between
the E6 and the NTGmice (p=1). Panel B. Time of onset of tumors. E6/E7 tumors and E7
only tumors arose earlier at an average of 19.8 and 19.1 weeks after initial DMBA treat-
ment. NTG and E6 mice had signiﬁcantly (pb0.05) longer time of average tumor onset
at 24.7 and 24.5 weeks, respectively.E7 has a strong oncogenic activity in anal carcinogenesis
Mice from each genotype, E6/E7, E7, E6 and NTG, were treated
with DMBA for 20 weeks using the protocol we had previously estab-
lished for inducing anal cancer in mice (Stelzer et al., 2010a, 2010b).
Eight weeks following the completion of DMBA treatments, the entire
perianal area was harvested, and scored for overt disease, then forma-
lin ﬁxed, embedded and every 30th 5uM section was stained with he-
matoxylin and eosin and scored histologically for the worst disease
ranging from normal, papilloma, atypia to carcinoma. MKT identiﬁed
lesions within each section and ﬁnal histopathological determinationwas made by HCP, a pathologist experienced in diagnosing the histo-
pathology of mouse tumors. The E7 only mice and E6/E7 mice had an
85% incidence of anal cancer which was signiﬁcantly higher than E6
only and NTG mice, 18% and 10% respectively (Table 1). Tumors
(86% of which were cancers) were larger in E7 and E6/E7 mice com-
pared to E6 and NTG mice (Fig. 2A). In addition, they arose at an ear-
lier time after initial DMBA treatment for E7 and E6/E7 mice, 19.1 and
19.8 weeks respectively, compared to E6 and NTG mice, 24.7 and
24.5 weeks (Fig. 2B). Cancers that arose in each genotype were of
squamous cell origin and, where they were not too large to deﬁne
their origin, half originated in the anal transition zone and the other
half at or near the anal exit (there were no differences between geno-
types in this distribution).
Biomarker analyses
Both MCM7 and p16 are well-validated markers for HPV-associat-
ed cancers. We therefore compared the staining patterns of tumors
arising in the various mouse genotypes for these two markers along
with markers for cell proliferation (BrdUrd) and differentiation (K10
and K14). NTG mouse cancers had BrdUrd and MCM7 staining only
at the basement membrane whereas E6, E7 and E6/E7 cancers had
BrdUrd and MCM7 positive cells throughout the epithelium and
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Fig. 3. Histopathology of anal cancer. Representative images of cancers from each genotype are shown. H&E stained sections showing keratin pearls and large atypical nuclei con-
sistent with squamous cell carcinoma. BrdUrd staining indicative of DNA synthesis is lowest in the NTG cancer as is MCM7 staining consistent with a lack of HPV oncoproteins. Also
shown are p16, K14 and K10 staining. See text for full discussion of results.
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favorably with results from biomarker studies in cervical cancers aris-
ing in the same mice (Shai et al., 2007). Anal cancers from all geno-
types were positive for both K14 and K10, markers for
undifferentiated and differentiated epithelia, respectively (Fig. 3).
This result correlates with the observation based upon analysis of
H&E stained sections of these same cancers that by and large they
are well-differentiated tumors. Exceptions are the anal cancers aris-
ing in the E6/E7 double transgenic mice in which some (representa-
tive example in Fig. 3) show comparatively low levels of K10
staining and less evidence for terminal epithelial cell differentiation
(i.e. absence of keratin pearls, see H&E stained section).
Discussion
In HPV-positive human cancers two viral genes, E6 and E7, are
preferentially expressed owing largely to the integration of the viral
genome into the host DNA (zur Hausen, 2009). Elucidating the role
of individual HPV oncogenes is vital as targeted therapeutic drugs
are developed for these oncoproteins and their speciﬁc activities. In
this study we show that E7 is the more potent oncogene for anal car-
cinogenesis. E7 is also the more potent oncogene for our mouse
models of cervical and head and neck HPV cancers. Each of these
models has a different co-carcinogen (DMBA for anal cancer, estrogen
for cervical cancer, and 4-NQO for head/neck cancer). Thus the choice
of co-carcinogen is not contributing to the dominance of E7 in causing
cancers in these relevant tissue types. Rather, we attribute the domi-
nance of E7 to its interactions with cellular factors within the epithe-
lium of each of these tissues. In head and neck cancer inactivation of
pRb partially accounted for E7 ability to induce cancer (Strati and
Lambert, 2007); however in the cervix, Rb was less important a target
(Balsitis et al., 2006). In contrast, p21 is a relevant target of E7 in the
cervix, but again its inactivation by E7 only accounts partially for E7's
oncogenic potential (Shin et al., 2009). Which cellular targets of E7
play a critical role in anal cancer remains to be determined.
A role of E6 in anal carcinogenesis was not clearly demonstrated
based upon the data from this study. This is not unlike our original
ﬁndings in the head and neck cancers, wherein E7 was again foundto be the dominant oncogene (Strati and Lambert, 2007). However,
by reducing the time of treatment with the co-carcinogen used in
the head/neck cancer model, we were able to clearly deﬁne a role
of E6 speciﬁcally in synergizing with E7 to cause head/neck cancer
(Jabbar et al., 2010). Such a synergy was originally observed in our
mouse model for cervical cancer (Riley et al., 2003), and is highly rel-
evant to HPV-associated human cancers, wherein these two onco-
genes are always found to be co-expressed. In the context of
cervical cancer studies, mutational analyses of E6 pointed to an im-
portance of E6's interaction with PDZ proteins in mediating E6's syn-
ergy with E7 (Shai et al., 2007). This activity of E6 is also largely
responsible for its induction of epithelial hyperplasia in the skin
(Simonson et al., 2005), a phenotype also observed in our hands in
the anal epithelium, on particular in the context of E6's co-expression
with E7 (Fig. 1). Lastly, we have identiﬁed the MTOR pathway to be
highly activated in both anal cancers, be they from humans or our
HPV16 transgenic mouse model, and both human and mouse anal
cancers responded well to treatment with rapamycin, the MTOR in-
hibitor (Stelzer et al., 2010a). Importantly, Munger and colleagues de-
termined that E6 speciﬁcally activates the MTOR pathway (Spangle
and Munger, 2010). Thus there are many reasons to predict that E6
can synergize with E7 to cause anal cancer. Were we to reduce the
time of treatment with DMBA, then we might uncover such a synergy
in the context of anal cancer, much like we did in the head/neck can-
cer model.
Materials and methods
Mice
Generation of K14E6 and K14E7 mice has been previously de-
scribed (Herber et al., 1996; Song et al., 1999). These mice were main-
tained on the inbred FVB/N genetic background. E6/E7 transgenic
mice were generated by crossing K14E6 females with K14E7 males.
All mice were kept in American Association for Accreditation of Labo-
ratory Animal Care-approved McArdle Laboratory Cancer Center Ani-
mal Care Facility and studies with them were carried out in
accordance to an approved animal protocol.
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All mice received intraperitoneal injections of bromo deoxyuracil
(BrdUrd)12.5 mg/mL in PBS at 10 μL/g body weight 1 hour prior to
sacriﬁce. Mice did not receive any type of perianal treatment prior
to sacriﬁce. All mice were between 6 and 8 weeks of age. Irradiated
mice were exposed to 12 Gy of ionizing radiation from a 137Cs source
24 hours prior to sacriﬁce. Nuclei in anal epithelium was scored as
positive (brown) or negative (blue) for BrdUrd based upon BrdUrd-
speciﬁc immunohistochemistry. A minimum of ﬁve high power ﬁelds
were counted for each group.
Immunohistochemistry
Immunohistochemistry staining was carried out as previously de-
scribed (Balsitis et al., 2003). Primary antibodies were applied over-
night at 4 °C at the following concentrations in 2.5% horse serum
(1:50 BrdUrd, Calbiochem; 1:200 antiMCM7, Neomarkers; 1:50 p16
(M156), Santa Cruz; 1:500 K10, Covance, 1:1000 K14, Covance).
DMBA induced anal carcinogenesis
Anal carcinogenesis was achieved as previously described using
the DMBA (dimethylbenz[a]anthracene) dose of 0.12 μmol (Stelzer
et al., 2010a, 2010b). Mice were monitored weekly for appearance
of overt tumors and size (diameter in mm) was measured at sacriﬁce.
Histological analysis
The anal canal tissue was ﬁxed in 10% formalin, parafﬁn embed-
ded, and serially sectioned at 5 μm. Every 30th section was stained
with H&E and histopathologically analyzed for hyperplasia, papillo-
ma, atypia, or carcinoma.
Statistical analysis
Two-sided Wilcoxon rank-sum test was used to determine signif-
icant differences in BrdUrd counts, tumor onset and tumor size at sac-
riﬁce. Two-sided Chi square test was used to determine differences in
rates of disease among mouse genotypes.
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